HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Positive 60.0%

Neg 0% Neu 0% Pos 60%

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.